Suven Life Sciences Share Price | Suven Life Sciences Stock Screener
SUVEN
Healthcare Technology
Share Price NSE
₹316.00
▼
-1.00 (-0.32%)
Share Price BSE
₹316.35
▼
-0.60 (-0.19%)
As of July 24, 2026, the Suven Life Sciences share price (NSE: SUVEN) is ₹316.00 on NSE and ₹316.35 on BSE, down 0.32% from the previous close, with shares trading between ₹311.20 and ₹320.05, and a 52-week range of ₹126.65–₹359.55.
Analyse SUVEN stock price history and track historical price performance.
Use the Suven Life Sciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Suven Life Sciences Market Cap
₹8,926.94 Cr.
SUVEN P/E Ratio (TTM)
-33.39
Suven Life Sciences P/B Ratio
10.98
EPS (TTM)
₹-12.13
Dividend Yield
-
Debt to Equity
-
SUVEN 52 Week High
₹359.55
Suven Life Sciences 52 Week Low
₹126.65
Operating Margin
-3331.00%
Profit Margin
-575.00%
SUVEN Revenue (TTM)
₹8.00
EBITDA
₹-44.00
Net Income
₹-46.00
Total Assets
₹624.00
Total Equity
₹591.00
Suven Life Sciences Share Price Chart
Screen Suven Life Sciences share price with an interactive chart. Analyse SUVEN price trends and volatility across different timeframes.
Suven Life Sciences Company Profile - Fundamental Screener
Screen Suven Life Sciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for SUVEN shares.
Sector
Healthcare
Industry
Healthcare Technology
Sub-Sector
Healthcare Technology
Segment
E
ISIN
INE495B01038
Suven Life Sciences Balance Sheet Screener
Screen SUVEN balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 624 | 135 | 285 | 389 | 108 | 128 | 182 | 303 | 919 | 816 |
| Current Assets | 547 | 76 | 257 | 252 | 67 | 103 | 66 | 281 | 570 | 492 |
| Fixed Assets | 77 | 60 | 28 | 37 | 38 | 21 | 25 | 22 | 308 | 306 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 2 | 2 | 1 | 3 | 4 | 5 | 12 | 25 | 30 | 30 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 591 | 110 | 270 | 375 | 96 | 108 | 143 | 239 | 767 | 667 |
| Share Capital | 26 | 22 | 22 | 22 | 15 | 13 | 13 | 13 | 13 | 13 |
| Reserves & Surplus | 565 | 88 | 248 | 354 | 82 | 58 | 131 | 226 | 755 | 654 |
Suven Life Sciences Income Statement Screener - Profit & Revenue Analysis
Screen Suven Life Sciences income statement and profit fundamentals.
Analyze SUVEN quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Suven Life Sciences share price evaluation.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8 | 6 | 5 | 3 | 3 | 3 | 7 | 5 | 7 | 9 | 16 | 9 | 8 | 5 | 5 |
| Expenses | 52 | 106 | 81 | 53 | 45 | 41 | 55 | 32 | 33 | 49 | 27 | 32 | 34 | 55 | 26 |
| EBITDA | -44 | -101 | -76 | -50 | -43 | -38 | -48 | -27 | -26 | -40 | -11 | -22 | -26 | -49 | -22 |
| Operating Profit % | -3331.00% | -3678.00% | -8671.00% | -2714.00% | -2981.00% | -2435.00% | -2032.00% | -3023.00% | -1267.00% | -1885.00% | -768.00% | -737.00% | -1208.00% | -1720.00% | -494.00% |
| Depreciation | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -46 | -102 | -77 | -52 | -44 | -39 | -50 | -28 | -28 | -42 | -13 | -24 | -28 | -51 | -23 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -46 | -102 | -77 | -52 | -44 | -39 | -50 | -28 | -27 | -42 | -13 | -24 | -28 | -51 | -23 |
| EPS | -2.02 | -4.55 | -3.48 | -2.36 | -2.02 | -1.79 | -2.27 | -1.29 | -1.22 | -1.92 | -0.58 | -1.10 | -1.17 | -2.90 | -1.51 |
Suven Life Sciences Cash Flow Screener - Liquidity Fundamentals
Screen SUVEN cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -154 | -116 | -116 | -128 | -96 | -135 | -53 | 70 | 109 | 68 |
| Investing Activities | 155 | 94 | -248 | -22 | 56 | 146 | 30 | -1 | -311 | -39 |
| Financing Activities | -1 | -1 | 396 | 146 | 35 | 3 | 5 | -52 | -30 | -68 |
| Net Cash Flow | 0 | -22 | 32 | -4 | -5 | 14 | -18 | 17 | -232 | -39 |
Suven Life Sciences Shareholding Pattern Screener
See Suven Life Sciences shareholding pattern with promoter, FII, and DII holdings.
Check Suven Life Sciences promoter holding and ownership changes for SUVEN on TickJournal.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jul | 2025-Jun | 2025-Mar | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 70.08% | 70.15% | 67.36% | 67.36% | 67.43% | 70.27% | 70.27% | 70.27% |
| FII Holding | 0.57% | 0.91% | 1.07% | 1.18% | 0.56% | 0.59% | 0.25% | 0.34% |
| DII Holding | 2.93% | 4.62% | 3.39% | 3.39% | 3.41% | 0.02% | 0.01% | 1.06% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 21.37% | 19.45% | 22.29% | 22.25% | 22.24% | 23.17% | 24.04% | 22.31% |
| Other Holding | 5.06% | 4.87% | 5.90% | 5.82% | 6.37% | 5.95% | 5.44% | 6.04% |
| Shareholder Count | 66,791 | 64,037 | 64,381 | 64,921 | 65,574 | 66,159 | 64,603 | 63,537 |
Suven Life Sciences Share Dividend Screener - Share Yield Analysis
Check Suven Life Sciences dividend history with payout and yield data.
View Suven Life Sciences dividend details including ex-dates and amounts for SUVEN stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹1.50 | 7.61% |
| 2018-March | ₹1.50 | 0.57% |
| 2017-March | ₹1.00 | 12.85% |
Suven Life Sciences Stock Index Membership
See which indices include Suven Life Sciences stock.
Check SUVEN index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
Suven Life Sciences Market Events Screener - Corporate Actions
Get Suven Life Sciences corporate actions including splits, bonuses, and buybacks.
Check Suven Life Sciences stock events that may affect SUVEN share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-25 | 2026-08-25 | Annual General Meeting | NA | 51.73% |
| 2026-05-13 | 2026-05-13 | Quarterly Result Announcement | NA | 4.67% |
| 2026-01-29 | 2026-01-29 | Quarterly Result Announcement | NA | -2.40% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | -5.22% |
| 2025-08-22 | 2025-08-22 | Annual General Meeting | NA | 53.37% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -13.24% |
| 2025-06-05 | 2025-06-05 | Extraordinary General Meeting | NA | 53.37% |
| 2025-05-13 | 2025-05-13 | Quarterly Result Announcement | NA | 16.60% |
| 2025-01-24 | 2025-01-24 | Quarterly Result Announcement | NA | -8.29% |
| 2024-10-29 | 2024-10-29 | Quarterly Result Announcement | NA | -7.61% |
| 2024-08-02 | 2024-08-02 | Annual General Meeting | NA | 26.09% |
| 2022-10-17 | 2022-10-18 | Rights | 1:2 | 4.83% |
Suven Life Sciences Competitors Screener - Peer Comparison
Screen SUVEN competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Syngene International | 16,857 | 53.17 | 3,809 | 2.56% | 317 | 39.15 |
| Indegene | 12,267 | 30.63 | 3,511 | 19.14% | 349 | 48.53 |
| Suven Life Sciences | 8,927 | -33.39 | 7 | -59.60% | -276 | 60.98 |
| Vimta Labs | 2,369 | 35.09 | 322 | 0.22% | 41 | 42.78 |
| Take Solutions | 296 | 26.23 | 54 | 431.27% | 11 | 25.20 |
| Bilcare | 146 | -8.45 | 734 | -9.05% | -21 | 53.19 |
| Jeevan Scientific Technology | 145 | 140.06 | 62 | 29.56% | 2 | 39.99 |
| Adeshwar Meditex | 25 | 33.09 | 56 | -33.21% | 1 | 24.11 |
| Vanta Bioscience | 18 | 168.60 | 2 | -13.33% | 0 | 19.48 |
Suven Life Sciences Company Announcements - News Screener
Screen SUVEN latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - | |
| 2026-07-20 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-20 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-07-16 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-07-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-08 | Revised Outcome Of The Meeting Of Board Of Directors- Incorporation Of Wholly Owned Subsidiary (WOS) In Singapore | - |
| 2026-07-08 | Incorporation Of Wholly Owned Subsidiary (WOS) In Singapore | - |
| 2026-07-08 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-07-08 | Announcement under Regulation 30 (LODR)-Allotment | - |
| 2026-07-08 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-06-26 | Closure of Trading Window | - |
| 2026-06-22 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-06-22 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-06-17 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-06-16 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-06-12 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-06-04 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-05-29 | Rectification Order For Assesment Year 2020-21 | - |
| 2026-05-19 | Clarification On Volume Movement Letter | - |
| 2026-05-19 | Clarification sought from Suven Life Sciences Ltd | - |